Labetuzumab govitecan | Antibody-Drug Conjugate inhibitor | Read Reviews & Product Use Citations

Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer.

CAS No. 1469876-18-3

Click to purchase products related to Labetuzumab govitecan

Purity & Quality Control

Batch: D404801 Purity: 99% Protein concentration: 4.91 mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective Antibody-Drug Conjugate Inhibitors

Biological Activity

Description	Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer.

References
[1] Dotan E, et al. J Clin Oncol. 2017;35(29):3338-3346. [2] Dotan Efrat, et al. Cancer Res (2016) 76 (14_Supplement): CT065.

References

Product Details

CAS No.	1469876-18-3
ADC antiody	Labetuzumab
ADC linker	Lysine; a maleimide-type cleavable linker
ADC cytotoxin	SN-38
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field